#ESMO26 Today the thoracic oncology community celebrates: 🏆 The major advances in the fight against lung cancer reported at @myESMO 🎉The birthday of @JordiRemon 🥳 (great discussant!) 🐣 The new member of the lung cancer family on the way!!! ….and the best ever pregnant discussant of all times @DrJNaidoo So happy to be part of this superfamily May God bless you all and our patients #ESMOAmbassadors

#ESMO26 Presidential 1 : #SCLC DeLLphi-305: Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC! #Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42. 80% of patients alive and 38% progression-free at 12 months The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨ @myESMO @SclcSMASHERS #ESMOAmbassadors

#ESMO26 : A great brainstorming summit on #SCLC organized by @LungSummit in a fully packed auditorium+overflow following yesterday’s announcement of DeLlphi-305; ➡️ The chemoIO landscape in 1L @MartinReck2 ➡️ T-cell engager clinical development @peters_solange ➡️ Management οf CRS and ICANS @g_mountzios ➡️ Sequencing and combinations @NReguart A heartfelt 🙏 for your presence, interaction and tons of questions!!! #ESMOAmbassadors

#ESMO26 Does Tarlatamab provide long term benefit to responding patients? ✅The answer is Yes! ➡️Extended F-UP of the Dellphi-304 trial shows that after 22m of F-UP Landmark 2-year OS was 30% vs 15% and sustained disease control in 24% of patients at > 52 weeks ❓We need to investigate the characteristics of those patients to understand how we can improve the outcomes of the 70% of patients who do not make it to two years @myESMO #ESMOAmbassadors

#ESMO26 Presidential 1 Excellent state-of-the art discussion on #Dellphi-305 by the 1@only @StephenVLiu emphasizing on: ➡️ 1L maintenance Tarla setting a new SoC with a mOS of>20 months ❓High attrition rate from induction to maintenance, need for earlier TCE ( Dellphi-312) ❌Only 19% of pts in control arm received 2L Tarla post-progression reflecting access hurdles ✅ Global access to Tarla will make innovation meaningful for our patients @@myESMO #ESMOAmbassadors

#SCLC therapeutic landscape is rapidly changing, with T-cell engagers, ADCs and bi-specifics moving fast to earlier lines of treatment and challenging the current treatment paradigm Thrilled to discuss the landscape with KOLs @peters_solange and @nicogirardcurie in a brain-storming discussion Follow the link below to access: #some #LCSM @SclcSMASHERS @LUNGevity @LungCancerEu

With #ASCO26 just around the corner, it is my great pleasure to present in the oral abstract session, alongside prominent colleagues and chairs, the intracranial efficacy data of #tarlatamab from #DeLLphi-304 trial, the first data on CNS efficacy of a T-cell engager in #SCLC. Stay tuned!! 📌 Sunday June 1st, 13:15-16:15, Hall D1 #SoMe #LCSM @SclcSMASHERS @OncoAlert @OncBrothers @PeerView @PortalOnconews @MedscapeOnc @VJOncology @ecancer @LungCancerEu @YoungLungCancer @HeSMO_X @HenryDunantGR

Farewell to another productive and exceptionally brainstorming @EORTC LCG meeting under the leadership and guidance of @JordiRemon @HendriksLizza @MarianaBrandao0 Huge 🙏 to Rafal Dziadziusco for a wonder honestly n beautiful Gdansk!! See you all next year in Athens!!!!

Best way to start the @EORTC lung cancer group meeting here in #Gdansk with a fascinating symposium focusing on #SCLC with amazing lectures by @bartolomiej @finn_corinne and @NReguart , including a deep dive in SCLC biology